# Spero Therapeutics, Inc.

Canonical: https://abierto.us/vendors/spero-therapeutics-inc-nx34pl7nzw24

- UEI: NX34PL7NZW24
- CAGE: 7SK81
- Location: Cambridge, MA
- Awards in window: 2 (13 transactions), $20,944,972 obligated, July 3, 2024 to July 20, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $17,520,435
- National Institutes of Health: 1 awards, $3,424,537

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $17,520,435
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $3,424,537

## Competition

- Full and Open Competition: 2 awards

## Largest awards

- 75A50118C00015 (definitive contract): $17,520,435, Barda - Aspr / Daappo / Barda DCMA. Modification P00015 the Purpose of This Bilateral Modification Is To: A) Increase the US Government Funding for Clin 0005 Option 4 from $12,498,467 by $11,697,110 to $24,195,577 and the Spero Cost Share from $63,204,595 by $14,683,133 to $77,887,. https://www.usaspending.gov/award/CONT_AWD_75A50118C00015_7505_-NONE-_-NONE-/
- 75N93021C00022 (definitive contract): $3,424,537, National Institutes of Health Niaid. To Advance Clinical and Non-Clinical Development of an Antibiotic Candidate.. https://www.usaspending.gov/award/CONT_AWD_75N93021C00022_7529_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/spero-therapeutics-inc-nx34pl7nzw24.